Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write
Ngalaba Ọgwụgwọ
Ọgwụgwọ Ndị A Maara

Ọgwụgwọ CAR-T maka ọtụtụ Myeloma (MM)

    Nchịkọta

    Ọrịa kansa dị iche iche (Multiple Myeloma (MM) bụ ụdị ọrịa kansa nke na-emetụta mkpụrụ ndụ plasma dị n'ime ụmị ọkpụkpụ. A maara ya maka ọdịdị ya dị mgbagwoju anya na nke na-agbanwe agbanwe, nke na-ebutekarị nlọghachi na iguzogide ọgwụgwọ ọdịnala. Ọ bụ ezie na ọgwụgwọ chemotherapy, mgbanwe mkpụrụ ndụ stem, na ọgwụ ọhụrụ emeela ka nsonaazụ ka mma, ọtụtụ ndị ọrịa na-emesịa na-eche nsogbu ọgwụgwọ ihu. Ọgwụgwọ CAR-T (Chimeric Antigen Receptor T-cell) bụ ọgwụgwọ dị egwu nke gosipụtara ihe ịga nke ọma dị ukwuu n'ịgwọ ọrịa myeloma ndị na-alaghachi azụ na ndị na-adịghị ike, na-enye ngwọta na-ekwe nkwa maka ndị ọrịa nwere obere nhọrọ.

    Kedu ihe bụ ọgwụgwọ CAR-T maka MM?

    Ọgwụgwọ CAR-T gụnyere ịgbanwe mkpụrụ ndụ T nke onye ọrịa ka ha mata ma wakpo mkpụrụ ndụ kansa nke ọma. Maka ọtụtụ myeloma, a na-emepụta mkpụrụ ndụ CAR-T ka ha lekwasị anya na BCMA (B-cell maturation antigen), protein dị n'elu mkpụrụ ndụ myeloma. Mgbe agbanwechara mkpụrụ ndụ ihe nketa ha, a na-etinye mkpụrụ ndụ T ndị a n'ime ahụ onye ọrịa, ebe ha na-achọ ma bibie mkpụrụ ndụ kansa, nke nwere ike ibute mgbaghara na ndụ ogologo oge.

    Uru Dị Mkpa nke Ọgwụgwọ CAR-T maka Ọtụtụ Myeloma

    • Ọganihu Dị Elu na Relapsed/Refractory MM: Ọgwụgwọ CAR-T egosila nnukwu ihe ịga nke ọma n'ahụ ndị ọrịa nwere myeloma multiple relapsed ma ọ bụ refractory, na-enwetakarị mbelata zuru oke ma ọ bụ obere ọnọdụ ọrịa fọdụrụ (MRD).
    • Nkọcha Ezubere IcheSite n'itinye aka na BCMA, ọgwụgwọ CAR-T na-awakpo mkpụrụ ndụ myeloma kpọmkwem, na-azọpụta anụ ahụ dị mma ma na-ebelata mmetụta ọjọọ ma e jiri ya tụnyere ọgwụgwọ ọdịnala.
    • Nhazi na Ihe ỌhụrụỌgwụgwọ a na-eji mkpụrụ ndụ T nke onye ọrịa ahụ, na-eme ka atụmatụ ọgwụgwọ nkeonwe dị oke mma. Nke a na-enyekwa aka belata ihe egwu nke ịjụ.
    • Nkwụghachi Ogologo OgeỌtụtụ ndị ọrịa a gwọrọ site na ọgwụgwọ CAR-T na-enweta mmeghachi omume na-adịgide adịgide, ụfọdụ na-enwe mgbaghara ruo ọtụtụ afọ, ọbụlagodi mgbe ọgwụgwọ ndị ọzọ dara ada.

    Usoro Ọgwụgwọ

    • Nchịkọta nke mkpụrụ ndụ TNzọụkwụ mbụ gụnyere ịnakọta mkpụrụ ndụ T site n'ọbara onye ọrịa site na iji leukapheresis, usoro yiri inye ọbara.
    • Ịrụzi mkpụrụ ndụ T: A na-eziga mkpụrụ ndụ T ndị a n'ụlọ nyocha, ebe a na-agbanwe ha ka ha gosipụta CAR nke BCMA kpọmkwem, na-eme ka ikike ha ịchọpụta ma gbuo mkpụrụ ndụ myeloma ka mma.
    • Ntinye nke mkpụrụ ndụ CAR-T: Mgbe emechara ka ọ gbasaa n'ime ụlọ nyocha ahụ, a na-etinye mkpụrụ ndụ T ndị e mepụtara ọhụrụ n'ime ọbara onye ọrịa site na iji IV.
    • Nlekota na MgbakeMgbe a mịnyechara ya ọgwụ, a na-enyocha ndị ọrịa maka mmetụta ọjọọ dịka ọrịa cytokine release syndrome (CRS) ma ọ bụ neurotoxicity. A na-ejikwa mmetụta ọjọọ ndị a eme ihe site na enyemaka ahụike na nlekota.

    Gịnị mere ị ga-eji họrọ ọgwụgwọ CAR-T nke BIOOCUS maka ọtụtụ myeloma?

    • Teknụzụ CAR-T nke kachasị ọhụrụBIOOCUS na-eji ọganihu kachasị ọhụrụ na teknụzụ CAR-T iji hụ na ọgwụgwọ kachasị mma na nsonaazụ kacha mma maka ndị ọrịa MM.
    • Ọkachamara Ahụike nke Class WorldwideNdị ọkachamara anyị na Hematology na immunotherapy na-enye nlekọta nkeonwe, na-ahụ na onye ọrịa ọ bụla na-enweta ọgwụgwọ kacha mma maka ọnọdụ pụrụ iche ha.
    • Ihe ndekọ egwu a nwapụtara: Anyị agwọọla ọtụtụ ndị ọrịa MM site na ọgwụgwọ CAR-T, ọtụtụ n'ime ha enwetawokwa mgbaghara dị ịrịba ama na nke na-adịgide ogologo oge.
    • Nkwado zuru oke maka Ndị Ọrịa Mba NileBIOOCUS na-enye nkwado zuru oke maka ndị ọrịa mba ofesi, na-eduzi gị site na usoro ọgwụgwọ ọ bụla, site na ndụmọdụ mbụ ruo na nlekọta mgbe ọgwụgwọ gasịrị.

    Ihe Akaebe Ahụike na Ọnụego Ihe Ịga nke Ọma

    Data Ọgwụ

    Ihe ngosi maka CD19+20CAR-T:Ndị ọrịa nwere lymphoma nke na-abụghị Hodgkin nke mkpụrụ ndụ B

    Ọnụego CR otu ọnwa

    Ọnụego PR otu ọnwa

    Ọnụego otu ọnwa OR

    CRS≥3

    CRES≥3

    71.95%(59/82)

    25.6(21/82)

    97.55(80/82)

    12.19%(10/82)

    0

    Ihe ngosi maka CD19+22CAR-T:Ọgwụgwọ nke ndị nwere ọrịa leukemia B-lymphocytic CD19 na-alaghachi azụ ma na-agbanwe agbanwe

    Ọnụego CR otu ọnwa

    Ọnụego PR otu ọnwa

    Ọnụego otu ọnwa OR

    CRS≥3

    CRES≥3

    92.1%(35/38)

    Pasentị 7.9 (3/38)

    100% (38/38)

    15.79%(6/38)

    0

    Ihe ngosi maka BCMACAR-T:Ọgwụgwọ nke myeloma dị iche iche na-alaghachi azụ na nke na-adịghị agbanwe agbanwe

    Ọnụego CR otu ọnwa

    Ọnụego PR otu ọnwa

    Ọnụego otu ọnwa OR

    CRS≥3

    CRES≥3

    72.41%(21/29)

    27.59%(8/29)

    100% (29/29)

    Pasentị 6.9 (2/29)

    0

    Submit An Free Inquiry

    Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

    AI Helps Write